0001808805
2020-01-01
2020-06-30
0001808805
us-gaap:CommonClassBMember
2020-09-18
0001808805
us-gaap:CommonClassAMember
2020-09-18
0001808805
2020-06-30
0001808805
us-gaap:CommonClassBMember
2020-06-30
0001808805
us-gaap:CommonClassAMember
2020-06-30
0001808805
us-gaap:SubsequentEventMember
us-gaap:CommonClassBMember
2020-08-06
0001808805
2020-03-27
2020-06-30
0001808805
us-gaap:CommonStockMember
us-gaap:CommonClassBMember
2020-03-26
0001808805
us-gaap:AdditionalPaidInCapitalMember
2020-03-26
0001808805
2020-03-26
0001808805
us-gaap:RetainedEarningsMember
2020-03-26
0001808805
us-gaap:CommonStockMember
us-gaap:CommonClassAMember
2020-03-26
0001808805
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2020-03-27
2020-06-30
0001808805
us-gaap:AdditionalPaidInCapitalMember
2020-03-27
2020-06-30
0001808805
us-gaap:RetainedEarningsMember
2020-03-27
2020-06-30
0001808805
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2020-03-27
2020-06-30
0001808805
us-gaap:CommonStockMember
us-gaap:CommonClassBMember
2020-06-30
0001808805
us-gaap:RetainedEarningsMember
2020-06-30
0001808805
us-gaap:AdditionalPaidInCapitalMember
2020-06-30
0001808805
us-gaap:CommonStockMember
us-gaap:CommonClassAMember
2020-06-30
0001808805
us-gaap:SubsequentEventMember
arya:PublicSharesMember
us-gaap:IPOMember
2020-08-11
2020-08-11
0001808805
us-gaap:SubsequentEventMember
arya:PublicSharesMember
us-gaap:OverAllotmentOptionMember
2020-08-11
2020-08-11
0001808805
arya:PrivatePlacementUnitsMember
us-gaap:SubsequentEventMember
2020-08-11
2020-08-11
0001808805
us-gaap:OverAllotmentOptionMember
arya:PublicSharesMember
us-gaap:SubsequentEventMember
2020-08-11
0001808805
arya:PrivatePlacementUnitsMember
us-gaap:SubsequentEventMember
2020-08-11
0001808805
us-gaap:SubsequentEventMember
us-gaap:IPOMember
arya:PublicSharesMember
2020-08-11
0001808805
us-gaap:SubsequentEventMember
2020-08-11
2020-08-11
0001808805
us-gaap:SubsequentEventMember
2020-08-11
0001808805
srt:MaximumMember
us-gaap:SubsequentEventMember
2020-08-11
0001808805
us-gaap:InvestorMember
2020-03-27
2020-06-30
0001808805
us-gaap:InvestorMember
arya:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember
2020-03-27
2020-06-30
0001808805
us-gaap:SubsequentEventMember
us-gaap:InvestorMember
arya:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember
2020-07-01
2020-08-10
0001808805
arya:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember
us-gaap:InvestorMember
us-gaap:SubsequentEventMember
2020-08-11
2020-08-11
0001808805
us-gaap:InvestorMember
arya:IndependentDirectorNomineesMember
us-gaap:SubsequentEventMember
2020-07-01
2020-07-31
0001808805
us-gaap:CommonClassBMember
us-gaap:InvestorMember
2020-04-02
2020-04-02
0001808805
us-gaap:PrivatePlacementMember
us-gaap:InvestorMember
2020-03-27
2020-06-30
0001808805
us-gaap:InvestorMember
us-gaap:CommonClassBMember
2020-04-02
0001808805
us-gaap:InvestorMember
us-gaap:CommonClassBMember
2020-06-30
0001808805
us-gaap:SubsequentEventMember
us-gaap:InvestorMember
us-gaap:CommonClassBMember
2020-08-11
0001808805
us-gaap:CommonClassBMember
us-gaap:InvestorMember
2020-03-27
2020-06-30
0001808805
srt:MinimumMember
us-gaap:CommonClassAMember
us-gaap:InvestorMember
2020-06-30
0001808805
us-gaap:PrivatePlacementMember
us-gaap:InvestorMember
2020-06-30
0001808805
us-gaap:CommonClassAMember
us-gaap:InvestorMember
2020-03-27
2020-06-30
0001808805
us-gaap:CommonClassAMember
srt:MinimumMember
us-gaap:InvestorMember
2020-03-27
2020-06-30
0001808805
us-gaap:InvestorMember
arya:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember
2020-04-02
2020-04-02
0001808805
arya:SponsorAffiliateOfSponsorOrCertainCompanyOfficersAndDirectorsMember
arya:WorkingCapitalLoansMember
2020-03-27
2020-06-30
0001808805
arya:WorkingCapitalLoansMember
arya:SponsorAffiliateOfSponsorOrCertainCompanyOfficersAndDirectorsMember
2020-06-30
0001808805
arya:AdministrativeSupportAgreementMember
us-gaap:InvestorMember
2020-03-27
2020-06-30
0001808805
arya:ForwardPurchaseArrangementMember
us-gaap:InvestorMember
2020-06-30
0001808805
us-gaap:OverAllotmentOptionMember
2020-03-27
2020-06-30
0001808805
us-gaap:SubsequentEventMember
us-gaap:OverAllotmentOptionMember
2020-08-11
2020-08-11
0001808805
us-gaap:CommonClassBMember
2020-04-02
0001808805
srt:MaximumMember
us-gaap:InvestorMember
us-gaap:SubsequentEventMember
us-gaap:CommonClassBMember
2020-08-06
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
9633
125000
24626
0
211326
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-style: italic;">Basis of Presentation</div><div><br /></div><div style="text-align: justify; color: #000000;">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the period from March 27, 2020 through June 30, 2020 are not necessarily indicative of the results that may be expected through December 31, 2020.</div><div><br /></div><div style="text-align: justify; color: #000000;">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form 8-K and the final prospectus filed by the Company with the SEC on August 17, 2020 and August 10, 2020, respectively.</div></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-weight: bold;">Note 2 — Summary of Significant Accounting Policies</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Basis of Presentation</div><div><br /></div><div style="text-align: justify; color: #000000;">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the period from March 27, 2020 through June 30, 2020 are not necessarily indicative of the results that may be expected through December 31, 2020.</div><div><br /></div><div style="text-align: justify; color: #000000;">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form 8-K and the final prospectus filed by the Company with the SEC on August 17, 2020 and August 10, 2020, respectively.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Use of Estimates</div><div><br /></div><div style="text-align: justify; color: #000000;">The preparation of the financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</div><div><br /></div><div style="text-align: justify; color: #000000;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Emerging Growth Company</div><div><br /></div><div style="text-align: justify; color: #000000;">Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Concentration of Credit Risk</div><div><br /></div><div style="text-align: justify; color: #000000;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Cash and Cash Equivalents</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2020.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Financial Instruments</div><div><br /></div><div style="text-align: justify; color: #000000;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the condensed balance sheet.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Net Loss Per Ordinary Share</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. At June 30, 2020, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the period presented.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Deferred Offering Costs Associated with the Initial Public Offering</div><div><br /></div><div style="text-align: justify; color: #000000;">Deferred offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that were directly related to the Initial Public Offering and that were charged to shareholder’s equity upon the completion of the Initial Public Offering in August 2020.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Income Taxes</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</div><div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><br /></div><div>FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2020. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the period from March 27, 2020 (inception) through June 30, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Recent Accounting Pronouncements</div><div><br /></div><div style="text-align: justify; color: #000000;">Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.</div></div>
0
0
0
0
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-style: italic;">Cash and Cash Equivalents</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2020.</div></div>
0
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-weight: bold;">Note 5 — Commitments & Contingencies</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic;">Registration Rights</div><div><br /></div><div style="text-align: justify; color: #000000;">The holders of Founder Shares and Private Placement Shares that may be issued upon conversion of working capital loans, are entitled to registration rights pursuant to a registration and shareholder rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up period, which occurs (i) in the case of the Founder Shares, in accordance with the letter agreement the Company’s initial shareholders entered into and (ii) in the case of the Private Placement Shares, 30 days after the completion of the Company’s Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</div><div style="text-align: justify; color: #000000;"><font style="font-style: italic;"><br /></font></div><div style="text-align: justify; color: #000000;"><font style="font-style: italic;">Underwriting Agreement<br /></font></div><div style="text-align: justify; color: #000000;"><font style="font-style: italic;"></font><br /></div><div style="text-align: justify; color: #000000;">The Company granted the underwriters a 45-day option from the final prospectus relating to the Initial Public Offering to purchase up to 1,950,000 additional Public Shares to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.  The underwriters fully exercised their over-allotment option on August 11, 2020.</div><div><br /></div><div style="text-align: justify; color: #000000;">The underwriters were paid a cash underwriting discount of $0.20 per Public Share, or approximately $3.0 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per Public Share, or approximately $5.2 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.</div></div>
0.0001
0.0001
0.0001
0.0001
0
3737500
3593750
20000000
479000000
0
3737500
3737500
374
0
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-style: italic;">Concentration of Credit Risk</div><div><br /></div><div style="text-align: justify; color: #000000;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</div></div>
1500000
10.00
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-style: italic;">Deferred Offering Costs Associated with the Initial Public Offering</div><div><br /></div><div style="text-align: justify; color: #000000;">Deferred offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that were directly related to the Initial Public Offering and that were charged to shareholder’s equity upon the completion of the Initial Public Offering in August 2020.</div></div>
211326
8800000
63410
0
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-style: italic;">Net Loss Per Ordinary Share</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. At June 30, 2020, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the period presented.</div></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-style: italic;">Financial Instruments</div><div><br /></div><div style="text-align: justify; color: #000000;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the condensed balance sheet.</div></div>
11717
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-style: italic;">Income Taxes</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</div><div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><br /></div><div>FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2020. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the period from March 27, 2020 (inception) through June 30, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.</div></div>
211326
198043
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="color: rgb(0, 0, 0); font-weight: bold;">Note 1 — Description of Organization and Business Operations</div><div><br /></div><div style="text-align: justify; color: #000000;">ARYA Sciences Acquisition Corp III (the “Company”) was incorporated as a Cayman Islands exempted company on March 27, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.</div><div><br /></div><div style="text-align: justify; color: #000000;">As of June 30, 2020, the Company had not commenced any operations. All activity for the period from March 27, 2020 (inception) through June 30, 2020 relates to the Company’s formation and the preparation of its initial public offering (the “Initial Public Offering”) described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company’s sponsor is ARYA Sciences Holdings III, a Cayman Islands exempted limited company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on August 6, 2020.  On August 11, 2020, the Company consummated its Initial Public Offering of 14,950,000 Class A ordinary shares (the “Public Shares”), including the 1,950,000 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $149.5 million, and incurring offering costs of approximately $8.8 million, inclusive of approximately $5.2 million in deferred underwriting commissions (Note 3).</div><div><br /></div><div style="text-align: justify; color: #000000;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 499,000 Class A ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share to the Sponsor, generating gross proceeds of approximately $5.0 million (Note 4).</div><div><br /></div><div style="text-align: justify; color: #000000;">Upon the closing of the Initial Public Offering and the Private Placement, $149.5 million ($10.00 per Class A ordinary share) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement were placed in a trust account (“Trust Account”), located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company acting as trustee, and was invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in money market fund meeting the conditions of paragraphs (d)(1), (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”).</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company will provide the holders (the “Public Shareholders”) of Public Shares, with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).</div><div style="text-align: justify; color: #000000;"><br /></div><div style="text-align: justify; color: #000000;">The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, only if a majority of the ordinary shares, represented in person or by proxy and entitled to vote thereon, voted at a shareholder meeting are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which the Company will adopt upon the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or vote at all. If the Company seeks shareholder approval in connection with a Business Combination, the initial shareholders (as defined below) have agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. Subsequent to the consummation of the Initial Public Offering, the Company will adopt an insider trading policy which will require insiders to: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the initial shareholders have agreed to waive their redemption rights with respect to their Founder Shares, Private Placement Shares and Public Shares in connection with the completion of a Business Combination.</div><div><br /></div><div style="text-align: justify; color: #000000;">Notwithstanding the foregoing, if the Company seeks shareholder approval of its Business Combination and does not conduct redemptions in connection with its Business Combination pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association will provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company.</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company’s Sponsor, officers and directors (the “initial shareholders”) have agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to provide holders of its Public Shares the right to have their shares redeemed in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete its Business Combination within 24 months from the closing of the Initial Public Offering, or August 11, 2022 (the “Combination Period”) or with respect to any other provision relating to the rights of Public Shareholders, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment.</div><div><br /></div><div style="text-align: justify; color: #000000;">If the Company has not completed a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay for its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.</div><div><br /></div><div style="text-align: justify; color: #000000;">The initial shareholders have agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per Public Share due to reductions in the value of the trust assets. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”).</div><div style="text-align: justify; color: #000000;"><br /></div><div style="text-align: justify; color: #000000;">Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (excluding the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</div><div><br /></div><div style="color: #000000; font-style: italic;">Liquidity and Capital Resources</div><div style="text-align: justify;"><br /></div><div style="text-align: justify; color: #000000;">At June 30, 2020, the Company had no cash and working capital deficit of approximately $198,000.</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company’s liquidity needs up to June 30, 2020 had been satisfied through the receipt of $25,000 from the Sponsor to cover certain expenses of the Company’s behalf in exchange for the issuance of the Founder Shares (as defined below), and a loan of approximately $63,000 pursuant to the Note issued to the Sponsor (Note 4). Subsequent to June 30, 2020, the Company’s liquidity needs had been satisfied with the remaining balance of the loan proceeds under the Note of approximately $137,000, and the proceeds from the consummation of the Private Placement not held in the Trust Account. The Company fully repaid the loan of $200,000 under the Note in full on August 11, 2020.  In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor may, but is not obligated to, provide the Company Working Capital Loans (see Note 4).</div><div><br /></div><div style="text-align: justify; color: rgb(0, 0, 0);">Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.</div><div style="text-align: justify; text-indent: 18pt;"><font style="color: #000000;"></font><br /></div><div style="text-align: justify; color: #000000;">Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that the specific impact is not readily determinable as of the date of the condensed financial statements were available to be issued. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div></div>
0
-11717
0
0
0
-11717
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-style: italic;">Recent Accounting Pronouncements</div><div><br /></div><div style="text-align: justify; color: #000000;">Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.</div></div>
0
3000000
0
0
0
0.0001
1000000
25000
149500000
5000000
5000000
63000
137000
11717
200000
300000
200000
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-weight: bold;">Note 4 — Related Party Transactions</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Founder Shares</div><div><br /></div><div style="text-align: justify; color: #000000;">On April 2, 2020, the Sponsor paid $25,000 to cover certain offering costs of the Company in consideration of 3,593,750 Class B ordinary shares, par value $0.0001, (the “Founder Shares”). In July 2020, the Sponsor transferred an aggregate of 90,000 Founder Shares to the Company’s independent director nominees. On August 6, 2020, the Company effected a share capitalization resulting in the initial shareholders holding 3,737,500 Founder Shares. All shares and the associated amounts have been retroactively restated to reflect the share capitalization. The Sponsor agreed to forfeit up to 487,500 Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriters, so that the Founder Shares would represent 20.0% of the Company’s issued and outstanding ordinary shares (excluding the Private Placement Shares) after the Initial Public Offering.  The underwriters fully exercised the over-allotment option on August 11, 2020; thus, these 487,500 Founder Shares were no longer subject to forfeiture.</div><div><br /></div><div style="text-align: justify; color: #000000;">The initial shareholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Private Placement Share</div><div><br /></div><div style="text-align: justify; color: #000000;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 499,000 Private Placement Shares, at a price of $10.00 per Private Placement Share to the Sponsor, generating gross proceeds of approximately $5.0 million.  The Private Placement Shares will not be transferable or salable until 30 days after the completion of the initial Business Combination.  A portion of the proceeds from the Private Placement Shares was added to the proceeds from the Initial Public Offering held in the Trust Account.</div><div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><br /></div><div>The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Shares until 30 days after the completion of the initial Business Combination.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Related Party Loans</div><div><br /></div><div style="text-align: justify; color: #000000;">On April 2, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover for expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan was non-interest bearing and payable upon the completion of the Initial Public Offering. As of June 30, 2020, the Company borrowed approximately $63,000 under the Note.  Subsequent to June 30, 2020, the Company received the remaining balance of the loan proceeds under the Note of approximately $137,000, for a total of $200,000 balance under the Note.  Upon the completion of the Initial Public Offering on August 11, 2020, the Note was fully repaid.</div><div><br /></div><div style="text-align: justify; color: #000000;">In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into shares of the post Business Combination entity at a price of $10.00 per share. The shares would be identical to the Private Placement Shares. To date, the Company had no outstanding borrowings under the Working Capital Loans.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Administrative Support Agreement</div><div><br /></div><div style="text-align: justify; color: #000000;">Commencing on the effective date of the registration statement on Form S-1 related to the Initial Public Offering through the earlier of consummation of the initial Business Combination or the Company’s liquidation, the Company will reimburse the Sponsor for office space, secretarial and administrative services provided to the Company in the amount of $10,000 per month.</div><div><br /></div><div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Forward Purchase Arrangement</div><div><br /></div><div style="text-align: justify; color: #000000;">The Sponsor has indicated an interest to purchase up to an aggregate of $25 million of the Company’s ordinary shares in a private placement that would occur concurrently with the consummation of the initial Business Combination. However, because indications of interest are not binding agreements or commitments to purchase, the Sponsor may determine not to purchase any such shares, or to purchase fewer shares than it has indicated an interest in purchasing. Furthermore, the Company is not under any obligation to sell any such shares.</div></div>
200000
-11717
12.00
10.00
0
0
0
3737500
10.00
10.00
10.00
3737500
14950000
1950000
499000
90000
3593750
499000
1950000
25000
374
24626
0
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-weight: bold;">Note 6 — Shareholders’ Equity</div><div><br /></div><div style="text-align: justify; color: #000000;"><font style="font-weight: bold; font-style: italic;">Class A Ordinary Shares -</font> The Company is authorized to issue 479,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of June 30, 2020, there were no Class A ordinary shares issued or outstanding.</div><div><br /></div><div style="text-align: justify; color: #000000;"><font style="font-weight: bold; font-style: italic;">Class B Ordinary Shares -</font> The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. On April 2, 2020, the Company issued 3,593,750 Class B ordinary shares. On August 6, 2020, the Company effected a share capitalization resulting in the initial shareholders holding 3,737,500 Founder Shares, of which up to 487,500 shares are subject to forfeiture to the Company by the Sponsor for no consideration to the extent that the underwriter’s over-allotment option is not exercised in full or in part, so that the initial shareholders would collectively own 20% of the Company’s issued and outstanding ordinary shares (excluding the Private Placement Shares and assuming the initial shareholders do not purchase any shares in the Initial Public Offering) (See Note 4). All shares and the associated amounts have been retroactively restated to reflect the share capitalization.</div><div><br /></div><div style="text-align: justify; color: #000000;">Holders of the Class A ordinary shares and holders of the Class B ordinary shares will vote together as a single class on all matters submitted to a vote of our shareholders, except as required by law or stock exchange rule; provided that only holders of the Class B ordinary shares have the right to vote on the election of the Company’s directors prior to the initial Business Combination and holders of a majority of the Company’s Class B ordinary shares may remove a member of the board of directors for any reason.</div><div><br /></div><div style="text-align: justify; color: #000000;">The Class B ordinary shares will automatically convert into Class A ordinary shares on the first business day following the consummation of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares) upon the consummation of the Initial Public Offering, plus (ii) the sum of the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Shares issued to the Sponsor, members of the Company’s management team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to one.</div><div><br /></div><div style="text-align: justify; color: #000000;"><font style="font-weight: bold; font-style: italic;">Preference Shares -</font> The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2020, there were no preference shares issued or outstanding.</div></div>
13283
0
0
0
0
0
374
-11717
24626
0
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Note 7 — Subsequent Events</div><div><br /></div><div style="text-align: justify; color: #000000;">The Company evaluated subsequent events and transactions that occurred up to the date unaudited condensed financial statements were available to be issued. Other than as described in Note 1, 3 and 4, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.</div></div>
0
0
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-style: italic;">Use of Estimates</div><div><br /></div><div style="text-align: justify; color: #000000;">The preparation of the financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</div><div><br /></div><div style="text-align: justify; color: #000000;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.</div></div>
3737500
false
--12-31
2020-06-30
NY
Yes
Non-accelerated Filer
ARYA Sciences Acquisition Corp III
0001808805
3737500
15449000
2020
Q2
10-Q
Yes
true
true
false
true
487500
487500
P45D
0.35
5200000
0.20
0.2
487500
1
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; color: #000000; font-weight: bold;">Note 3 — Initial Public Offering</div><div><br /></div><div style="text-align: justify; color: #000000;">On August 11, 2020, the Company consummated its Initial Public Offering of 14,950,000 Public Shares, including the 1,950,000 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $149.5 million, and incurring offering costs of approximately $8.8 million, inclusive of approximately $5.2 million in deferred underwriting commissions.</div></div>
5200000
51693
125000
25000
25000
9633
-198000
100000
25000000
10000
P30D
P20D
P1Y
487500
P150D
0.200
On August 6, 2020, the Company effected share capitalizations resulting in the initial shareholders holding 3,737,500 Class B ordinary shares. All shares and associated amounts have been retroactively restated to reflect the share capitalization (see Note 4).
This number includes up to 487,500 shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. The underwriters fully exercised the over-allotment option on August 11, 2020; thus, these shares were no longer subject to forfeiture.